Waon therapy for managing chronic heart failure - Results from a multicenter prospective randomized WAON-CHF study

Chuwa Tei, Teruhiko Imamura, Koichiro Kinugawa, Teruo Inoue, Tohru Masuyama, Hiroshi Inoue, Hirofumi Noike, Toshihiro Muramatsu, Yasuchika Takeishi, Keijiro Saku, Kazumasa Harada, Hiroyuki Daida, Youichi Kobayashi, Nobuhisa Hagiwara, Masatoshi Nagayama, Shinichi Momomura, Kazuya Yonezawa, Hiroshi Itoh, Satoshi Gojo, Makoto AkaishiMasaaki Miyata, Mitsuru Ohishi, Ryozo Nagai, Shunei Kyo, Minoru Ono, Hitonobu Tomoike, Yasuo Oohashi, Shigeru Toyoda, Takuro Kubozono, Mitsuo Sobajima, Kanta Hujimi, Shinichi Hirotani, Takahiro Nakagami, Masamitsu Sugie, Itimon Nakamura, Miho Yokoyama, Akiomi Yoshihisa, Shinji Koba, Tsuyoshi Shiga, Megumi Shimada, Yuko Yamamoto, Ai Okazaki, Tomohito Suzuki, Nobutoshi Sugiyama

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Waon therapy improves heart failure (HF) symptoms, but further evidence in patients with advanced HF remains uncertain. Methods and Results: In 19 institutes, we prospectively enrolled hospitalized patients with advanced HF, who had plasma levels of B-type natriuretic peptide (BNP) >500 pg/ml on admission and BNP >300 pg/ml regardless of more than 1 week of medical therapy. Enrolled patients were randomized into Waon therapy or control groups. Waon therapy was performed once daily for 10 days with a far infrared-ray dry sauna maintained at 60°C for 15 min, followed by bed rest for 30 min covered with a blanket. The primary endpoint was the ratio of BNP before and after treatment. In total, 76 Waon therapy and 73 control patients (mean age 66 years, men 61%, mean plasma BNP 777 pg/ml) were studied. The groups differed only in body mass index and the frequency of diabetes. The plasma BNP, NYHA classification, 6-min walk distance (6MWD), and cardiothoracic ratio significantly improved only in the Waon therapy group. Improvements in NYHA classification, 6MWD, and cardiothoracic ratio were significant in the Waon therapy group, although the change in plasma BNP did not reach statistical significance. No serious adverse events were observed in either group. Conclusions: Waon therapy, a holistic soothing warmth therapy, showed clinical advantages in safety and efficacy among patients with advanced HF.

Original languageEnglish
Pages (from-to)827-834
Number of pages8
JournalCirculation Journal
Volume80
Issue number4
DOIs
Publication statusPublished - Mar 25 2016

    Fingerprint

Keywords

  • Advanced heart failure
  • B-type natriuretic peptide
  • Nitric oxide
  • Vascular failure
  • Waon therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Tei, C., Imamura, T., Kinugawa, K., Inoue, T., Masuyama, T., Inoue, H., Noike, H., Muramatsu, T., Takeishi, Y., Saku, K., Harada, K., Daida, H., Kobayashi, Y., Hagiwara, N., Nagayama, M., Momomura, S., Yonezawa, K., Itoh, H., Gojo, S., ... Sugiyama, N. (2016). Waon therapy for managing chronic heart failure - Results from a multicenter prospective randomized WAON-CHF study. Circulation Journal, 80(4), 827-834. https://doi.org/10.1253/circj.CJ-16-0051